JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 5
DOI:10.33266/1024-6177-2025-70-5-98-103
T.F. Malivanova, T.A. Astrelina, I.V. Kobzeva, Y.B. Suchkova, D.Y. Usupzhanova,
V.A. Brunchukov, V.A. Nikitina, A.I. Golovkova, A.S. Ostashkin, E.S. Lubaeva,
M.Yu. Sukhova, Yu.D. Udalov
Heterogeneity of the Early Radiation-Induced Skin Damage to Adjuvant Radiation Therapy of Breast Cancer Patients Allele TNF-308A Carriers
A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: Tatyana Feodorovna Malivanova, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: The use of ionizing radiation is a fundamental approach in the complex treatment of oncological diseases, including breast cancer (BC), the most common localization of malignancies in women. The degree of early radiation-induced skin damage (ERSD), a common complication of adjuvant radiation therapy (ART), can be considered as a criterion of individual radio sensitivity. An important link in the immune response to the damaging effects of ionizing radiation is the pro-inflammatory cytokine tumor necrosis factor (TNF). The TNF gene occupies a central position in the HLA gene complex and has a number of single-nucleotide polymorphisms. Approximately half of the carriers of the minor allele of TNF-308A/G polymorphism may be included in the ancestral haplotype AH8.1. The aim of the study was to assess the effect of polymorphisms of the TNF gene and genes of the HLA complex on the degree of ERSD in patients with breast cancer during the course of ART.
Material and methods: The study included 145 BC patients who underwent a course of ART (2 Gy in 25 fractions). The degree of ERSD was determined by a radiologist. Polymorphisms of genes TNF (–863C/A, –308G/A, –238G/A), HSPA1B+1267A/G and IKBL-62T/A and marker alleles of haplotype AH8.1 (HLA-A*01, HLA-B*08, HLA-DRB1*03) were determined by the PCR-SSP and PCR-RFLP.
Results: ERSD was detected in all BC patients during the course of ART: grade I – 57.9 %, grade II – 35.9 %, grade III – 6.2 %. Three genetic comparison groups were identified: carriers of the allele TNF-308A and simultaneously three marker alleles of haplotype AH8.1 (11.7 %); carriers of the allele TNF-308A without the AH8.1 haplotype (11.0 %); carriers of the wild allele homozygote TNF-308GG (77.3 %). The percentages of BC patients with grade II-III ERSD were significantly higher in carriers of the TNF-308A allele without the AH8.1 haplotype than in other BC patients (75.0 % and 38.0 %, respectively, p=0.0065; RR=1.97, 95 % CI [1.38, 2.83]). An increase in the proportion of BC patients with grade II-III ERSD with additional TNF-863CC homozygote to 85.7 %, compared with 37.4% for other breast cancer patients (p=0.0009), further increases the relative risk to RR=2.92, 95 % CI [1.68, 3.12]. The inclusion of other studied polymorphisms in the analysis did not have an additional effect.
Conclusion: For the first time, the heterogeneity of the reaction of allele TNF-308A carriers to radiation therapy has been revealed, which manifests itself depending on the inclusion or non-inclusion of this allele in the ancestral haplotype AH8.1 of the HLA complex. A genetic group with increased individual radio sensitivity has been identified as TNF-308A carriers without the haplotype AH8.1.
Keywords: adjuvant radiation therapy, early radiation-induced skin damage, breast cancer, tumor necrosis factor
For citation: Malivanova TF, Astrelina TA, Kobzeva IV, Suchkova YB, Usupzhanova DY, BrunchukovVA, Nikitina VA, Golovkova AI, Ostashkin AS, Lubaeva ES, Sukhova MYu, Udalov YuD. Heterogeneity of the Early Radiation-Induced Skin Damage to Adjuvant Radiation Therapy of Breast Cancer Patients Allele TNF-308A Carriers. Medical Radiology and Radiation Safety. 2025;70(5):98–103. (In Russian). DOI:10.33266/1024-6177-2025-70-5-98-103
References
1. Bennardo L., Passante M., Cameli N., Cristaudo A., Patruno C., Nistico S.P., Silvestri M. Skin Manifestations after Ionizing Radiation Exposure: a Systematic Review. Bioengineering 2021;8:153. doi: 10.3390/bioengineering8110153.
2. Smith A.O., Ju W., Adzraku S.Y., Wenyi L., Yuting C., Qiao J., Xu K., Zeng L. Gamma Radiation Induce Inflammasome Signaling and Pyroptosis in Microvascular Endothelial Cells. J Inflamm Res. 2021;14:3277-3288. doi: 10.2147/JIR.S318812.
3. De Sanctis V.D., Agolli L., Visco V., Monaco F., Muni R., Spagnoli A., Campanella B., Valeriani M., Minniti G., Osti M.F., Amanti C., Pellegrini P., Brunetti S., Costantini A., Alfo M., Torrisi M.R., Marchetti P., Enrici R.M. Cytokines, Fatigue, and Cutaneous Erythema in Early Stage Breast Cancer Patients Receiving Adjuvant Radiation Therapy. Biomed Res Int. 2014:523568. doi: 10.1155/2014/523568.
4. Canedo-Dorantes L., Canedo-Ayala M. Skin Acute Wound Healing: A Comprehensive Review. Int J Inflam. 2019:3706315. doi: 10.1155/2019/3706315.
5. Kulski J.K., Suzuki S., Shiina T. Human Leukocyte Antigen Super-Locus: Nexus of Genomic Supergenes, SNPs, Indels, Transcripts, and Haplotypes. Hum Genome Var. 2022;9;1:49. doi: 10.1038/s41439-022-00226-5.
6. Aly T.A., Eller E., Ide A., Gowan K., Babu S.R., Erlich H.A., Rewers M.J., Eisenbarth G.S., Fain P.R. Multi-SNP Analysis of MHC Region: Remarkable Conservation of HLA-A1-B8-DR3 Haplotype. Diabetes. 2006;55;5:1265-9. doi: 10.2337/db05-1276.
7. Talbot C.J., Tanteles G.A., Barnett G.C., Burnet N.G., Chang-Claude J., Coles C.E., Davidson S., Dunning A.M., Mills J., Murray R.J.S., Popanda O., Seibold P., West C.M.L., Yarnold J.R., Symonds R.P. A Replicated Association between Polymorphisms Near TNFα and Risk for Adverse Reactions to Radiotherapy. Br J Cancer. 2012;107;4:748-53. doi: 10.1038/bjc.2012.290.
8. Cordoba E.E., Lacunza E., Abba M.C., Fernandez E., Guerci A.M. Single Nucleotide Polymorphisms in ATM, TNF-α and IL6 Genes and Risk of Radiotoxicity in Breast Cancer Patients. Mutat Res Genet Toxicol Environ Mutagen. 2018;836;Pt B:84-89. doi: 10.1016/j.mrgentox.2018.06.005.
9. Malivanova T.F., Astrelina T.A., Kobzeva I.V., Nikitina V.A., Suchkova Y.B., Ostashkin A.S., Usupzhanova D.Y., Dobrovolskaya E.I., Brunchukov V.A., Rastorgueva A.A., Lomonosova E. E., Lubaeva E.S., Kretova E.Y., Stepanyants N.G., Sukhova M.Y., Samoilov A.S. Autoimmune Haplotype AH8.1 Normalizes the Level of Tumor Necrosis Factor in the Blood Sera of Breast-Cancer Patients. Mol. Genet. Microbiol. Virol. 2023;38:34-40. doi: 10.3103/S089141682301007X.
10. Elahi M.M., Asotra K., Matata B.M., Mastana S.S. Tumor Necrosis Factor Alpha -308 Gene Locus Promoter Polymorphism: an Analysis of Association with Health and Disease. Biochim Biophys Acta. 2009 Mar;1792;3:163-72. doi: 10.1016/j.bbadis.2009.01.007.
11. Pol J., Paillet J., Plantureux C., Kroemer G. Beneficial Autoimmunity and Maladaptive Inflammation Shape Epidemiological Links between Cancer and Immune-Inflammatory Diseases. Oncoimmunology. 2022;11;1:2029299. doi: 10.1080/2162402X.2022.202929912.
12. Shah A.A., Igusa T., Goldman D., Li J., Casciola-Rosen L., Rosen A., Petri M. Association of Systemic Lupus Erythematosus Autoantibody Diversity with Breast Cancer Protection. Arthritis Res Ther. 2021;23;1:64. doi: 10.1186/s13075-021-02449-3.
13. Barnett G.C., West C.M.L., Dunning A.M., Elliott R.M., Coles C.E., Pharoah P.D.P., Burnet N.G. Nat Rev Cancer. 2009;9;2:134-42. doi: 10.1038/nrc2587.
14. Pereira S., Orlandi E., Deneuve S., Barcellini A., Chalaszczyk A., Behm-Ansmant I., Hettal L., Rancati T., Vogin G., Thariat J. The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: a Narrative Review. Cancers 2022;14:6252. doi: 10.3390/cancers14246252.
15. Xia C., Qin L., Wang Y., Yao L., Shia B., Wu S-Y. Risk Factors and Specific Cancer Types of Second Primary Malignancies in Patients with Breast Cancer Receiving Adjuvant Radiotherapy: a Case-Control Cohort Study Based on the SEER Database. Am J Cancer Res. 2022;12;6:2744-2756. URL: www.ajcr.us /ISSN:2156-6976/ajcr0142447.
16. Rezaei S.J., Eid E., Tang J.Y., Kurian A.W., Kwong B.Y., Linos E. Incidence of Nonkeratinocyte Skin Cancer After Breast Cancer Radiation Therapy. JAMA Network Open. 2024;7;3:e241632. doi: 10.1001/jamanetworkopen.2024.1632.
17. Маливанова Т.Ф., Алфёрова Е.В., Осташкин А.С., Астрелина Т.А., Мазуренко Н.Н. Общая выживаемость больных раком молочной железы зависит от сочетания полиморфизмов гена фактора некроза опухоли и HLA-гаплотипов // Молекулярная генетика, микробиология и вирусология. 2020. Т.38. №1. С. 40-48 [Malivanova T.F., Alforova Ye.V., Ostashkin A.S., Astrelina T.A., Mazurenko N.N. Breast Cancer Patients Overall Survival Depends on a Combination of the Polymorphisms of Tumor Necrosis Factor Gene and HLA-Haplotypes. Molekulyarnaya Genetika, Mikrobiologiya i Virusologiya = Molecular Genetics, Microbiology and Virology. 2020;38;1:40-48 (In Russ.)]. doi: 10.17116/molgen2020380114.
18. Simman R., Bach K., Abbas F., Klomparens K., Brickman B.J. Management of Radiation-Induced Tissue Injuries: a Review of Current Treatment Strategies. Plast Reconstr Surg Glob Open. 2023 Jun 16;11;6:e5043. doi: 10.1097/GOX.0000000000005043.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.05.2025. Accepted for publication: 25.06.2025.